Press releases

Lipum AB (publ) announces that the first part of the clinical phase 1 study, where healthy subjects received a single dose of the drug candidate SOL-116...
Lipum AB (publ), which has developed the biological drug candidate SOL-116 for treatment of chronic inflammatory diseases such as rheumatoid arthritis...
Lipum AB (publ) ("Lipum") announces its Nomination Committee for the Annual General Meeting 2024. In accordance with the decision at the Annual...
Lipum AB (publ) is strengthening its leadership when going into phase II by appointing Ola Sandborgh as its new CEO where he takes over the helm from Einar...
Lipum AB (publ) has terminated the liquidity provider assignment with Erik Penser Bank AB and has appointed Carnegie Investment Bank AB as new liquidity...
Lipum (publ), a clinical stage biopharmaceutical company focused on chronic inflammatory diseases, today announced that the Board of Directors has appointed...
Lipum AB (publ) has published the interim report for period July to September for 2023. Below is a summary, a complete report (only in Swedish) is available...
Lipum (publ), a clinical stage biopharmaceutical company focused on chronic inflammatory diseases, today announced its participation in the following upcoming...
Lipum AB (publ) has published the interim report for period January to June for 2023. Below is a summary, a complete report (only in Swedish) is available...
Lipum AB (publ) today reported that the scientific publication titled “Effects of bile salt-stimulated lipase on blood cells and associations with...

Investor relations